Omeros Stock Price

0.78 (13.61%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 999,206
Bid Price 6.49
Ask Price 6.76
News -
Day High 6.8899


52 Week Range


Day Low 5.46
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Omeros Corporation OMER NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.78 13.61% 6.51 20:00:00
Open Price Low Price High Price Close Price Prev Close
5.70 5.46 6.8899 6.83 5.73
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,840 999,206 $ 6.02 $ 6,011,736 - 1.855 - 16.57
Last Trade Time Type Quantity Stock Price Currency
19:59:14 25 $ 6.65 USD


Draw Mode:

Omeros Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 408.37M 62.73M 60.20M $ -1,000.00 $ - 3.12 1.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 52.50k 4.20%

more financials information »

Omeros News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OMER Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.596.88994.495.06712,3911.9241.83%
1 Month3.906.88993.634.29779,5882.6166.92%
3 Months3.076.88991.8553.291,542,6673.44112.05%
6 Months6.117.4551.8553.901,045,8560.406.55%
1 Year14.4716.571.8556.041,069,919-7.96-55.01%
3 Years15.0825.491.85511.33832,813-8.57-56.83%
5 Years22.3827.001.85513.41823,905-15.87-70.91%

Omeros Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220807 18:51:20